Zusammensetzung und Wirkmechanismen von Adjuvanzien in zugelassenen viralen Impfstoffen

Wagner, Ralf; Hildt, Eberhard

doi:10.1007/s00103-019-02921-1

Cited by 11 publications

(6 citation statements)

References 70 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Both MPL-A and CpG (deoxycytidylate-phosphate-deoxyguanylate) motifs present in plasmid DNA have adjuvant activity and are capable of stimulating DC to produce pro-inflammatory cytokines and activate T cells [17,33]. Vaccine formulations with MPL-A+CpG have previously been demonstrated to be immunogenic [22].…”

Section: Discussionmentioning

confidence: 99%

“…Solid lipid nanoparticle lipoplexes have been demonstrated to effectively deliver siRNA and plasmid DNA in vitro [9,[12][13][14][15][16] but there are no reports of adjuvant-modified solid lipid nanoparticles (SLNs) as a DNA vaccine delivery system. Monophosphoryl lipid A (MPL-A) is a non-toxic chemically modified lipopolysaccharide (LPS) analogue which acts as a potent Toll-like receptor 4 (TLR4) agonist, and has been licensed for use in commercial vaccines Ceravix (Human Papillomavirus) and Shingrix (Herpes zoster virus) [17,18]. The incorporation of MPL-A as an adjuvant lipid to the SLN-A nanoparticles affords an immunogenic structural component of the lipoplex complex, which may increase antigen-specific immune responses in vivo.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Solid Lipid Nanoparticle Carrier Platform Containing Synthetic TLR4 Agonist Mediates Non-Viral DNA Vaccine Delivery

et al. 2020

View full text Add to dashboard Cite

There is a growing demand for better delivery systems to improve the stability and efficacy of DNA vaccines. Here we report the synthesis of a non-viral DNA vaccine delivery system using a novel adjuvanted solid lipid nanoparticle (SLN-A) platform as a carrier for a DNA vaccine candidate encoding the Urease alpha (UreA) antigen from Helicobacter pylori. Cationic SLN-A particles containing monophosphoryl lipid A (adjuvant) were synthesised by a modified solvent-emulsification method and were investigated for their morphology, zeta potential and in vitro transfection capacity. Particles were found to bind plasmid DNA to form lipoplexes, which were characterised by electron microscopy, dynamic light scattering and fluorescence microscopy. Cellular uptake studies confirmed particle uptake within 3 h, and intracellular localisation within endosomal compartments. In vitro studies further confirmed the ability of SLN-A particles to stimulate expression of pro-inflammatory cytokine tumor necrosis factor alpha (TNF-α) in human macrophage-like Tohoku Hospital Pediatrics-1 (THP-1) cells. Lipoplexes were found to be biocompatible and could be efficiently transfected in murine immune cells for expression of recombinant H. pylori antigen Urease A, demonstrating their potential as a DNA vaccine delivery system.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Solid Lipid Nanoparticle Carrier Platform Containing Synthetic TLR4 Agonist Mediates Non-Viral DNA Vaccine Delivery

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Aus dem fraktionierten Extrakt der Rinde des Seifenrindenbaums (Quillaja saponaria) werden die Fraktionen A und C verwendet, die die Komponenten Matrix A und C in Form von Nanopartikeln enthalten. Weitere Bestandteile von Matrix M sind phosphatgepufferte Salzlösung (PBS), Cholesterol und Phosphatidylcholin [ 26 , 27 ]. Saponin ist auch Bestandteil der Adjuvanzien ISCOM und AS01B.…”

Section: Impfstoffklassenunclassified

“…Es handelt sich bei CpG1018 um ein unmethyliertes, 22 Nukleotide umfassendes Oligomer. CpG1018 bewirkt eine deutliche Th1-Polarisierung der Immunantwort [ 27 ]. Zwar fördert CpG1018 die Reifung von DCs, hat jedoch keinen wesentlichen Einfluss auf die Freisetzung von Interferon (IFN-)α.…”

Section: Impfstoffklassenunclassified

Übersicht über die in der EU zugelassenen COVID-19-Impfstoffe – von der Technologie über die klinische Prüfung zur Zulassung

Hildt

2022

Bundesgesundheitsbl

View full text Add to dashboard Cite

ZusammenfassungDerzeit (Stand Juli 2022) sind in der EU 6 verschiedene COVID-19-Impfstoffe zugelassen. Diese umfassen 2 mRNA-basierte Impfstoffe (BNT162b2, Comirnaty® und mRNA-1273, Spikevax®), 2 auf einem adenoviralen Vektor basierende Impfstoffe (AZD1222, Vaxzevria® und Ad26.COV2.S, Jcovden®) sowie den Untereinheitenimpfstoff Nuvaxovid® (NVX-CoV2373) und den Inaktivatvirus-Impfstoff VLA2001. Obgleich diese Impfstoffe auf unterschiedlichen Technologien basieren, ist allen die Verwendung des Spike-Proteins von SARS-CoV‑2 als Antigen gemein.Diese Übersicht beschreibt die Charakteristika ihrer Zusammensetzung, ihre Wirksamkeit und den Einfluss verschiedener Faktoren auf die Wirksamkeit. Des Weiteren wird das Zulassungsverfahren erläutert und die Faktoren werden identifiziert, welche zu der bisher noch nicht dagewesenen Schnelligkeit in der Entwicklung und Zulassung von Impfstoffen gegen einen pandemischen Erreger beigetragen haben.

show abstract

“…адъюванты, которые включены в состав зарегистрированных вакцин для человека в Европе, США и России (против гриппа, гепатита А, гепатита В, вируса папилломы человека, малярии и др. ); приведена их характеристика, отражены эффекты, лежащие в основе проявления адъювантного действия [24,27,[35][36][37][38][39][40][41][42].…”

Section: стимуляция иммунного ответа с помощью адъювантовunclassified

Immune Response Induced by Immunisation with Antiviral Vaccines

Алпатова¹,

Авдеева²,

Гайдерова³

et al. 2020

Biopreparaty. Profilaktika, diagnostika, lechenie

View full text Add to dashboard Cite

The review is devoted to specific aspects of the development of post-vaccination immunity following immunisation with different types of antiviral vaccines, as well as to ways of increasing immunogenicity of vaccines and effectiveness of preventive vaccination. Vaccines containing highly purified and recombinant antigens obtained using modern technologies have lower reactogenicity and a higher safety profile, but are less immunogenic compared to live vaccines. Effective vaccines have not been developed for many viral infections yet. Therefore, it is critical to search for ways to enhance immunogenic properties of vaccines in order to increase the efficiency of vaccination, and to develop new vaccine formulations that provide reliable protection of the body against infection. The aim of the paper was to analyse specific aspects of immune response development following immunisation with antiviral vaccines, and approaches to increasing their immunogenicity using adjuvants. It reviews different types of antiviral vaccines, as well as specific aspects of immune response development depending on the nature of a specific antigen. The paper substantiates the use of adjuvants to enhance and regulate the induced immune response. It analyses mechanisms that determine the stimulating effect of adjuvants and summarises data on the adjuvants used in the licensed vaccines for human use. The authors highlight the need for further research to increase the efficiency of vaccination and suggest that one of potential solutions is the use of adjuvants based on recombinant human cytokines.

show abstract

Zusammensetzung und Wirkmechanismen von Adjuvanzien in zugelassenen viralen Impfstoffen

Cited by 11 publications

References 70 publications

Solid Lipid Nanoparticle Carrier Platform Containing Synthetic TLR4 Agonist Mediates Non-Viral DNA Vaccine Delivery

Solid Lipid Nanoparticle Carrier Platform Containing Synthetic TLR4 Agonist Mediates Non-Viral DNA Vaccine Delivery

Übersicht über die in der EU zugelassenen COVID-19-Impfstoffe – von der Technologie über die klinische Prüfung zur Zulassung

Immune Response Induced by Immunisation with Antiviral Vaccines

Contact Info

Product

Resources

About